Intensive uric acid-lowering therapy in CKD patients: the protocol for a randomized controlled trial

[1]  Kenneth G Saag,et al.  Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout , 2018, The New England journal of medicine.

[2]  M. Oka,et al.  A highly sensitive assay of human plasma xanthine oxidoreductase activity using stable isotope-labeled xanthine and LC/TQMS. , 2016, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[3]  T. Ninomiya,et al.  Serum Uric Acid as a Risk Factor for Chronic Kidney Disease in a Japanese Community　- The Hisayama Study. , 2016, Circulation journal : official journal of the Japanese Circulation Society.

[4]  Y. Hayashino,et al.  Association of serum uric acid levels with the risk of development or progression of albuminuria among Japanese patients with type 2 diabetes: a prospective cohort study [Diabetes Distress and Care Registry at Tenri (DDCRT 10)] , 2016, Acta Diabetologica.

[5]  Y. Ohashi,et al.  Association between Hypouricemia and Reduced Kidney Function: A Cross-Sectional Population-Based Study in Japan , 2015, American Journal of Nephrology.

[6]  Y. Kanno,et al.  Uric Acid Level Has a U-Shaped Association with Loss of Kidney Function in Healthy People: A Prospective Cohort Study , 2015, PloS one.

[7]  T. Mochizuki,et al.  Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease , 2014, Clinical Rheumatology.

[8]  K. Kimura.  Preface: evidence-based clinical practice guidelines for CKD—an abridged English version , 2014, Clinical and Experimental Nephrology.

[9]  I. Hisatome,et al.  Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout , 2014, Clinical and Experimental Nephrology.

[10]  I. Kubota,et al.  The association between serum uric acid and renal damage in a community-based population: the Takahata study , 2013, Clinical and Experimental Nephrology.

[11]  H. Rakugi,et al.  Febuxostat suppressed renal ischemia-reperfusion injury via reduced oxidative stress. , 2012, Biochemical and biophysical research communications.

[12]  Li-sheng Liu,et al.  The association between plasma uric acid and renal function decline in a Chinese population-based cohort. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[13]  Chirag R Parikh,et al.  Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. , 2012, Kidney international.

[14]  Y. Solak,et al.  A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[15]  G. Bellomo,et al.  ORIGINAL INVESTIGATIONS Pathogenesis and Treatment of Kidney Disease Association of Uric Acid With Change in Kidney Function in Healthy Normotensive Individuals , 2010 .

[16]  M. Goicoechea,et al.  Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[17]  Duk-Hee Kang,et al.  Oxidative stress with an activation of the renin–angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction , 2010, Journal of hypertension.

[18]  B. Satirapoj,et al.  Relationship between serum uric acid levels with chronic kidney disease in a Southeast Asian population , 2010, Nephrology.

[19]  S. Ito,et al.  Clinical Practice Guidebook for Diagnosis and Treatment of Chronic Kidney Disease , 2009 .

[20]  R. Oberbauer,et al.  Elevated uric acid increases the risk for kidney disease. , 2008, Journal of the American Society of Nephrology : JASN.

[21]  F. Turgut,et al.  Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions , 2007, International Urology and Nephrology.

[22]  J. Wetzels,et al.  Macroalbuminuria is a better risk marker than low estimated GFR to identify individuals at risk for accelerated GFR loss in population screening. , 2006, Journal of the American Society of Nephrology : JASN.

[23]  D. Levy,et al.  Low-Grade Albuminuria and Incidence of Cardiovascular Disease Events in Nonhypertensive and Nondiabetic Individuals: The Framingham Heart Study , 2005, Circulation.

[24]  B. Brenner,et al.  Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. , 2005, Journal of the American Society of Nephrology : JASN.

[25]  G. Bakris,et al.  The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. , 2005, Archives of internal medicine.

[26]  M. Nieminen,et al.  Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients: Losartan Intervention for Endpoint Reduction in Hypertension Study , 2005, Hypertension.

[27]  T. Igarashi,et al.  Exercise-induced acute renal failure associated with renal hypouricaemia: results of a questionnaire-based survey in Japan. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[28]  M. Nieminen,et al.  Albuminuria and Cardiovascular Risk in Hypertensive Patients with Left Ventricular Hypertrophy: The LIFE Study , 2003, Annals of Internal Medicine.

[29]  K. Iseki,et al.  Proteinuria and the risk of developing end-stage renal disease. , 2003, Kidney international.

[30]  T. Nakagawa,et al.  Hyperuricemia Causes Glomerular Hypertrophy in the Rat , 2002, American Journal of Nephrology.

[31]  K. Iseki,et al.  Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. , 2001, Hypertension research : official journal of the Japanese Society of Hypertension.

[32]  S. Yusuf,et al.  Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. , 2001, JAMA.

[33]  T. Greene,et al.  Blood Pressure Control, Proteinuria, and the Progression of Renal Disease , 1995, Annals of Internal Medicine.

[34]  M. Fukuda,et al.  Recurrence of acute renal failure and renal hypouricaemia , 1993, Pediatric Nephrology.

[35]  Japanese Society of Nephrology.  Evidence-based Clinical Practice Guideline for CKD 2013 , 2014, Clinical and Experimental Nephrology.

[36]  K. Leung,et al.  Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[37]  Michael J Lysaght,et al.  Maintenance dialysis population dynamics: current trends and long-term implications. , 2002, Journal of the American Society of Nephrology : JASN.

[38]  Lysaght Mj,et al.  Maintenance Dialysis Population Dynamics: Current Trends and Long-Term Implications , 2002 .

[39]  T. Greene,et al.  Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. , 1995, Annals of internal medicine.

[40]  K. Hande,et al.  Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. , 1984, The American journal of medicine.